LU91133I2 - Vesicare 10mg et 5 mg solifenacinum succinatum 10 mg et 5 mg. - Google Patents

Vesicare 10mg et 5 mg solifenacinum succinatum 10 mg et 5 mg.

Info

Publication number
LU91133I2
LU91133I2 LU91133C LU91133C LU91133I2 LU 91133 I2 LU91133 I2 LU 91133I2 LU 91133 C LU91133 C LU 91133C LU 91133 C LU91133 C LU 91133C LU 91133 I2 LU91133 I2 LU 91133I2
Authority
LU
Luxembourg
Prior art keywords
mg
succinatum
solifenacinum
vesicare
10mg
Prior art date
Application number
LU91133C
Other languages
English (en)
Other versions
LU91133I9 (fr
Original Assignee
Yamanouchi Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to JP32704594 priority Critical
Priority to PCT/JP1995/002713 priority patent/WO1996020194A1/fr
Application filed by Yamanouchi Pharma Co Ltd filed Critical Yamanouchi Pharma Co Ltd
Publication of LU91133I2 publication Critical patent/LU91133I2/fr
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=18194699&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91133(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Publication of LU91133I9 publication Critical patent/LU91133I9/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D221/00Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04Ortho- or peri-condensed ring systems
    • C07D221/06Ring systems of three rings
    • C07D221/10Aza-phenanthrenes
    • C07D221/12Phenanthridines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D453/00Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09KMATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K19/00Liquid crystal materials
    • C09K19/04Liquid crystal materials characterised by the chemical structure of the liquid crystal components, e.g. by a specific unit
    • C09K19/06Non-steroidal liquid crystal compounds
    • C09K19/34Non-steroidal liquid crystal compounds containing at least one heterocyclic ring
    • C09K19/3441Non-steroidal liquid crystal compounds containing at least one heterocyclic ring having nitrogen as hetero atom
    • C09K19/3444Non-steroidal liquid crystal compounds containing at least one heterocyclic ring having nitrogen as hetero atom the heterocyclic ring being a six-membered aromatic ring containing one nitrogen atom, e.g. pyridine
LU91133C 1994-12-28 2005-01-28 LU91133I9 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP32704594 1994-12-28
PCT/JP1995/002713 WO1996020194A1 (fr) 1994-12-28 1995-12-27 Nouveaux derives de quinuclidine et composition pharmaceutique les contenant

Publications (2)

Publication Number Publication Date
LU91133I2 true LU91133I2 (fr) 2005-03-29
LU91133I9 LU91133I9 (fr) 2018-08-01

Family

ID=18194699

Family Applications (1)

Application Number Title Priority Date Filing Date
LU91133C LU91133I9 (fr) 1994-12-28 2005-01-28

Country Status (23)

Country Link
US (2) US6017927A (fr)
EP (1) EP0801067B1 (fr)
JP (1) JP3014457B2 (fr)
KR (1) KR100386487B1 (fr)
CN (1) CN1045601C (fr)
AT (1) AT233761T (fr)
AU (1) AU695616B2 (fr)
CA (1) CA2208839C (fr)
DE (3) DE122004000048I2 (fr)
DK (1) DK0801067T3 (fr)
ES (1) ES2193208T3 (fr)
FI (1) FI115631B (fr)
HU (1) HU223778B1 (fr)
LU (1) LU91133I9 (fr)
MX (1) MX9704880A (fr)
NL (1) NL300141I1 (fr)
NO (4) NO2005012I1 (fr)
NZ (1) NZ298144A (fr)
PL (1) PL182344B1 (fr)
PT (1) PT801067E (fr)
RU (1) RU2143432C1 (fr)
TW (1) TW305842B (fr)
WO (1) WO1996020194A1 (fr)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100137358A1 (en) * 1996-11-05 2010-06-03 Dr. Reddy's Laboratories Ltd. Solifenacin compositions
FR2772378B1 (fr) * 1997-12-12 2000-02-04 Synthelabo Derives d'imidazole, leur preparation et leur application en therapeutique
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
JP2001316670A (ja) * 2000-05-02 2001-11-16 Dainippon Ink & Chem Inc 液晶組成物
TR200400420T4 (tr) * 2000-06-27 2004-03-22 Laboratorios S.A.L.V.A.T., S.A. Arilalkilaminlerden türetilmiş karbamatlar.
AT305468T (de) * 2000-12-22 2005-10-15 Almirall Prodesfarma Ag Chinuclidincarbamat derivate und deren verwendung als m3 antagonisten
JP4295985B2 (ja) 2000-12-28 2009-07-15 ラボラトリオス・アルミラル・ソシエダッド・アノニマLaboratorios Almirall S.A. 新規なキヌクリジン誘導体およびそれを含む医薬組成物
CN1270708C (zh) 2001-07-10 2006-08-23 安斯泰来制药有限公司 间质性膀胱炎治疗用医药组合物
WO2003053966A2 (fr) 2001-12-20 2003-07-03 Laboratorios S.A.L.V.A.T., S.A. Derives de 1-alkyl-1- azoniabicyclo[2.2.2]octane carbamate
US20060035923A1 (en) * 2002-06-07 2006-02-16 Rian Van Meeteren Overactive bladder treating drug
ES2203327B1 (es) 2002-06-21 2005-06-16 Almirall Prodesfarma, S.A. Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen.
ES2204295B1 (es) 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de quinuclidina-amida.
EA200500173A1 (ru) 2002-07-08 2005-08-25 Рэнбакси Лабораториз Лимитед Производные 3,6-дизамещенного азабицикло[3.1.0]гексана в качестве антагонистов мускариновых рецепторов
CN100436414C (zh) 2003-04-11 2008-11-26 兰贝克赛实验室有限公司 作为毒蕈碱受体拮抗剂的氮杂双环衍生物
WO2004014853A1 (fr) 2002-07-31 2004-02-19 Ranbaxy Laboratories Limited Derives 3,6-disubstitues d'azabicyclo [3.1.0]hexane utilises comme antagonistes des recepteurs muscariniques
WO2004014363A1 (fr) 2002-08-09 2004-02-19 Ranbaxy Laboratories Limited Derives d'azabicyclo[3.1.0] hexane 3,6-disubstitues, utiles en tant qu'agonistes de recepteurs muscariniques
WO2004018422A1 (fr) 2002-08-23 2004-03-04 Ranbaxy Laboratories Limited Derives d'azabicyclo(3.1.0)hexanes 3,6-disubstitues contenant fluoro et sulfonylamino, utilises comme antagonistes des recepteurs de muscarine
MXPA05003398A (es) * 2002-10-29 2005-06-22 Pharmacia & Upjohn Co Llc Compuestos de amonio cuaternario.
AT400553T (de) 2002-12-10 2008-07-15 Ranbaxy Lab Ltd 3,6-disubstituierte azabicyclo 3.1.0 - hexanderivative als antagonisten des muscarinrezeptors
ES2288641T3 (es) * 2002-12-20 2008-01-16 Dynogen Pharmaceuticals Inc. Metodo para tratar trastornos indoloros de la vejiga usando moduladores de canales del calcio de la subunidad alfa2-delta.
US7501443B2 (en) 2002-12-23 2009-03-10 Ranbaxy Laboratories Limited Flavaxate derivatives as muscarinic receptor antagonists
WO2004056767A1 (fr) 2002-12-23 2004-07-08 Ranbaxy Laboratories Limited Derives de 1-substitues-3-pyrrolidines comme antagonistes de recepteurs muscariniques
US7488748B2 (en) 2003-01-28 2009-02-10 Ranbaxy Laboratories Limited 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
DK1492519T3 (da) * 2003-03-21 2007-03-05 Dynogen Pharmaceuticals Inc Fremgangsmåder til behandling af lidelser i den nedre urinvej ved anvendelse af alfa-2-delta-underenhedscalciumkanalsmodulatorer med glat muskel-modulatorer
AU2003214520A1 (en) 2003-04-09 2004-11-01 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
AU2003223010A1 (en) 2003-04-10 2004-11-01 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
US7592359B2 (en) 2003-04-10 2009-09-22 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
WO2004091597A2 (fr) * 2003-04-15 2004-10-28 Pharmacia & Upjohn Company Llc Procede pour traiter le syndrome du colon irritable
US20050175689A1 (en) * 2003-10-27 2005-08-11 Yamanouchi Pharmaceutical Co., Ltd. Coated fine particles containing drug for intrabuccally fast disintegrating tablet
WO2005075474A1 (fr) * 2004-02-09 2005-08-18 Astellas Pharma Inc. Composition contenant du succinate de solifenacine
WO2005077364A1 (fr) * 2004-02-18 2005-08-25 Yamanouchi Pharmaceutical Co., Ltd. Préparation transdermique de solifénacine et procédé d'amélioration de la perméabilité transdermique de celle-ci
JPWO2005087231A1 (ja) 2004-03-16 2008-01-24 アステラス製薬株式会社 ソリフェナシン含有組成物
CA2560080A1 (fr) * 2004-03-16 2005-09-22 Astellas Pharma Inc. Composition contenant de la solifenacine
ES2397307T3 (es) * 2004-03-25 2013-03-06 Astellas Pharma Inc. Composición de solifenacina o una sal de la misma para su uso en una formulación solida
ZA200608614B (en) 2004-03-25 2008-06-25 Astellas Pharma Inc Composition for solid pharmaceutical preparation of solifenacin or salt thereof
WO2006035280A1 (fr) * 2004-09-27 2006-04-06 Ranbaxy Laboratories Limited Antagonistes des recepteurs muscariniques
WO2006035303A1 (fr) * 2004-09-29 2006-04-06 Ranbaxy Laboratories Limited Antagonistes de recepteurs muscariniques
KR20070098889A (ko) * 2004-12-27 2007-10-05 아스텔라스세이야쿠 가부시키가이샤 솔리페나신 또는 그의 염의 안정한 입자상 의약 조성물
CZ23089U1 (cs) * 2004-12-27 2011-12-28 Astellas Pharma Inc. Stabilní granulovaná farmaceutická kompozice solifenacinu nebo jeho soli
CA2599158C (fr) * 2005-02-25 2011-01-25 Astellas Pharma Inc. Agent pharmaceutique comprenant de la solifenacine
JP3701964B1 (ja) 2005-03-08 2005-10-05 アステラス製薬株式会社 キヌクリジン誘導体の新規な塩
US20080255188A1 (en) * 2005-07-11 2008-10-16 Naresh Kumar Muscarinic Receptor Antagonists
US7815939B2 (en) 2005-07-20 2010-10-19 Astellas Pharma Inc. Coated fine particles containing drug for intrabuccally fast disintegrating dosage forms
AU2006305619A1 (en) 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Pharmaceutical compositions of muscarinic receptor antagonists
EP1879867A2 (fr) * 2005-12-21 2008-01-23 Teva Pharmaceutical Industries Ltd Procedes de preparation de solifenacine
CZ300699B6 (cs) 2006-06-21 2009-07-22 Zentiva, A. S. Zpusob prípravy solifenacinu
WO2008011462A2 (fr) * 2006-07-19 2008-01-24 Dr. Reddy's Laboratories Ltd. Procédé de fabrication de solifénacine et de ses sels
ES2298049B1 (es) 2006-07-21 2009-10-20 Laboratorios Almirall S.A. Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano.
US20080114028A1 (en) * 2006-07-24 2008-05-15 Tamas Koltai Process for preparing polymorphic forms of solifenacin succinate
WO2008019055A2 (fr) * 2006-08-03 2008-02-14 Teva Pharmaceutical Industries Ltd. Procédé de dédoublement optique de 1-phényl-1,2,3,4-tétrahydroisoquinoléine
TW200825084A (en) * 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
WO2008062282A2 (fr) * 2006-11-22 2008-05-29 Medichem S.A. Procédé perfectionné pour la synthèse de solifénacine
CZ300692B6 (cs) * 2006-12-22 2009-07-15 Zentiva, A. S. Zpusob prípravy solifenacinu
US7741489B2 (en) * 2007-03-30 2010-06-22 Medichem S.A. Process for the synthesis of solifenacin
EP2146693A2 (fr) * 2007-04-11 2010-01-27 Dr. Reddy's Laboratories Ltd. Compositions à base de solifénacine
US20090099365A1 (en) * 2007-07-13 2009-04-16 Nurit Perlman Processes for solifenacin preparation
EP2172201A4 (fr) * 2007-07-20 2011-07-06 Astellas Pharma Inc Composition pharmaceutique pour une amélioration du symptôme des voies urinaires inférieures associé à une prostatomégalie
EP2018850A1 (fr) * 2007-07-24 2009-01-28 Ratiopharm GmbH Composition pharmaceutique comportant de la solifénacine ou sel acceptable pharmaceutiquement
WO2009057685A1 (fr) 2007-11-02 2009-05-07 Astellas Pharma Inc. Composition pharmaceutique pour traiter une vessie hyperactive
WO2009087664A1 (fr) * 2007-12-04 2009-07-16 Cadila Healthcare Limited Procédé de préparation d'une solifénacine base de pureté chimique et de pureté chirale et de ses sels
US8476297B2 (en) 2007-12-04 2013-07-02 Amgen Inc. TRP-M8 receptor ligands and their use in treatments
ITMI20080195A1 (it) 2008-02-08 2009-08-09 Dipharma Francis Srl Procedimento per la preparazione di solifenacin
EP2100598A1 (fr) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Composition à inhaler comprenant aclidinium pour le traitement de l'asthme et de maladies respiratoires obstructives chroniques
EP2100599A1 (fr) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Composition à inhaler comprenant aclidinium pour le traitement de l'asthme et de maladies respiratoires obstructives chroniques
US8404701B2 (en) 2008-03-27 2013-03-26 Chase Pharmaceuticals Corporation Use and composition for treating dementia
PL385264A1 (en) 2008-05-23 2009-12-07 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Method of production of enantiomerically pure (S)-1-phenyl-1, 2, 3, 4-tetrahydroizochinoline
PL385265A1 (xx) * 2008-05-23 2009-12-07 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania solifenacyny i/lub jej soli o wysokiej czystości farmaceutycznej
EP3067353B1 (fr) 2008-07-29 2017-11-22 KRKA, D.D., Novo Mesto Procédé de préparation de sels de solifénacine et leur inclusion dans des formes posologiques pharmaceutiques
EP2181707A1 (fr) 2008-11-04 2010-05-05 Astellas Ireland Co., Ltd. Utilisation combinée d'un antagoniste de récepteur alpha-adrénergique et d'un agent anti-muscarinique
RU2580652C2 (ru) 2009-02-04 2016-04-10 Астеллас Фарма Инк. Фармацевтическая композиция для орального введения
WO2010103529A1 (fr) * 2009-03-09 2010-09-16 Megafine Pharma(P) Ltd. Nouveau procédé de préparation de la solifénacine et nouvel intermédiaire dans sa préparation
EP2415472A4 (fr) 2009-03-30 2013-02-20 Astellas Pharma Inc Composition pharmaceutique solide contenant un corps amorphe de solifénacine
WO2011048607A1 (fr) * 2009-09-25 2011-04-28 Cadila Healthcare Limited Procédés de préparation de solifénacine ou d'un de ses sels
PL390214A1 (en) 2010-01-18 2011-08-01 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Method of the solifenacin succinate manufacturing
US8729056B2 (en) 2010-03-31 2014-05-20 Ono Pharmaceutical Co., Ltd. Preventive and/or therapeutic agent of hand-foot syndrome
EP2563123B1 (fr) 2010-04-30 2018-04-25 Merck Sharp & Dohme Corp. Nouveaux agonistes du récepteur bêta 3 adrénergique
EA023294B1 (ru) 2010-05-19 2016-05-31 Астеллас Фарма Инк. Фармацевтическая композиция, содержащая солифенацин
WO2012001481A1 (fr) 2010-06-28 2012-01-05 Aurobindo Pharma Limited Nouveau procédé pour la préparation de succinate de solifénacine
WO2012004264A1 (fr) 2010-07-05 2012-01-12 Ragactives, S.L.U. Sels de solifénacine
WO2012062916A1 (fr) 2010-11-11 2012-05-18 Hexal Ag Succinate de solifénacine cristallin
EP2510928A1 (fr) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium pour l'amélioration du sommeil des patients avec des maldadies respiratoires
MX348723B (es) 2011-05-10 2017-06-27 Theravida Inc Combinaciones de solifenacina y estimulantes salivales para el tratamiento de la vejiga hiperactiva.
US20140228575A1 (en) 2011-06-22 2014-08-14 Isochem Process for the Preparation of Solifenacin and Salts Thereof
KR101365849B1 (ko) 2012-03-28 2014-02-24 경동제약 주식회사 솔리페나신 또는 그의 염의 제조방법 및 이에 사용되는 신규 중간체
CN104411687A (zh) 2012-07-02 2015-03-11 法尔玛赞公司 一种用于制备索非那新或其盐的方法
JPWO2014034860A1 (ja) 2012-08-31 2016-08-08 アステラス製薬株式会社 経口投与用医薬組成物
CN103787969B (zh) 2012-10-30 2016-07-06 上海京新生物医药有限公司 一种(1s)-1-苯基-3,4-二氢-2(1h)-异喹啉甲酸酯的制备方法
WO2014086927A1 (fr) * 2012-12-06 2014-06-12 Chiesi Farmaceutici S.P.A. Composés ayant une activité antagoniste du récepteur muscarinique et agoniste du récepteur bêta2 adrénergique
EP2778167A1 (fr) 2013-03-11 2014-09-17 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Composition pharmaceutique comprenant solifenacin ou l'un de ses sels pharmaceutiquement acceptable
AU2014292722B2 (en) * 2013-07-13 2017-03-09 Beijing Fswelcome Technology Development Co., Ltd Quinine compounds, and optical isomers, preparation method and medical use thereof
CN104592221A (zh) * 2015-01-26 2015-05-06 中山奕安泰医药科技有限公司 一种合成索非那新的工艺
KR20160146428A (ko) 2015-06-12 2016-12-21 한미정밀화학주식회사 솔리페나신 또는 그의 약학적으로 허용되는 염과 락토즈를 포함하는 안정한 무정형 솔리페나신 약학 조성물 및 그의 제조방법
TW201927783A (zh) 2017-12-12 2019-07-16 美商阿爾庫達醫療公司 顆粒體蛋白前體調節劑及其使用方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0247266B1 (fr) * 1986-01-07 1993-03-10 Beecham Group Plc Dérivés d'indole ayant une chaîne latérale azabicyclique, procédé pour leur préparation, produits intermédiaires et compositions pharmaceutiques
IT1231238B (it) * 1987-09-21 1991-11-26 Angeli Inst Spa Derivati ammidinici
GB9023023D0 (en) * 1990-10-23 1990-12-05 Barlow Richard B Pharmaceutical compositions
GB9202443D0 (en) * 1992-02-05 1992-03-18 Fujisawa Pharmaceutical Co A novel substituted-acetamide compound and a process for the preparation thereof
JPH076635A (ja) * 1993-06-18 1995-01-10 Sony Corp 信号伝送ケーブル
AU7545894A (en) * 1993-09-02 1995-03-22 Yamanouchi Pharmaceutical Co., Ltd. Carbamate derivative and medicine containing the same
JPH07258250A (ja) * 1994-03-25 1995-10-09 Yamanouchi Pharmaceut Co Ltd エステル誘導体
AT339121T (de) * 2002-11-27 2006-10-15 Selmac S R L Vorrichtung zum positionieren und spannen geformter teile und damit ausgerüstete maschine

Also Published As

Publication number Publication date
MX9704880A (es) 1997-10-31
NO973027L (no) 1997-08-28
DE69529844T2 (de) 2004-03-04
US6017927A (en) 2000-01-25
NO2005012I1 (no) 2005-06-06
NO318026B1 (no) 2005-01-24
HU223778B1 (hu) 2005-01-28
EP0801067A4 (fr) 1998-03-11
LU91133A9 (fr)
AT233761T (de) 2003-03-15
PT801067E (pt) 2003-07-31
FI972775D0 (fr)
DE122004000048I2 (de) 2006-02-02
EP0801067A1 (fr) 1997-10-15
HUT77006A (hu) 1998-03-02
AU695616B2 (en) 1998-08-20
CN1171109A (zh) 1998-01-21
NZ298144A (en) 1998-04-27
CA2208839A1 (fr) 1996-07-04
NL300141I1 (nl) 2004-04-01
CN1045601C (zh) 1999-10-13
AU4355396A (en) 1996-07-19
DE69529844D1 (de) 2003-04-10
JP3014457B2 (ja) 2000-02-28
KR987000303A (ko) 1998-03-30
CA2208839C (fr) 2006-01-31
NL300141I2 (nl) 2004-04-01
KR100386487B1 (ko) 2003-09-26
FI115631B1 (fr)
FI972775A (fi) 1997-08-22
FI115631B (fi) 2005-06-15
NO2005016I1 (no) 2005-08-29
TW305842B (fr) 1997-05-21
NO2005016I2 (no) 2008-02-11
PL321019A1 (en) 1997-11-24
NO2017055I1 (no) 2017-11-06
PL182344B1 (en) 2001-12-31
LU91133I9 (fr) 2018-08-01
NO973027D0 (no) 1997-06-27
EP0801067B1 (fr) 2003-03-05
NO2017055I2 (no) 2017-11-06
DK0801067T3 (da) 2003-06-30
ES2193208T3 (es) 2003-11-01
JPH09508401A (ja) 1997-08-26
DE122004000048I1 (de) 2005-04-21
WO1996020194A1 (fr) 1996-07-04
FI972775A0 (fi) 1997-06-27
RU2143432C1 (ru) 1999-12-27
DK801067T3 (fr)
US6174896B1 (en) 2001-01-16

Similar Documents

Publication Publication Date Title
FI945001A (fi) Virtauskohdisteinen katetri
NO301369B1 (no) 1-aminoetylindolderivater
NO301637B1 (no) 1-aminoetylindolderivater
FI952515A0 (fi) Siirrännäismateriaali
FR2713225B1 (fr) N-pipéridino-3-pyrazolecarboxamide substitué.
FI953489A0 (fi) 2,6-diaminopuriinijohdannaisia
FI920291A0 (fi) Planeringsfoerfarande och -system foer cellulaert radionaet.
FI923693A0 (fi) Radiotelefonens bruksystem.
FR2681524B1 (fr) Implant cristallinien.
FI955296A (fi) Itsesulkeutuva järjestely
FI962004A (fi) Vesiliukoisia aktiivisia polyeteeniglykolisulfoneja
FI922939A0 (fi) Knappipett.
FR2710521B1 (fr) Elévateur de pénis.
FI990207A (fi) Enantiomeeripuhtaat diatsabisyklo(4.3.0)nonaanijohdannaiset
NO323078B1 (no) Mifroemulsjonsforkonsentrat og mikroemulsjonssammensetning.
DK0724519T3 (da) Værdipapir
NO303173B1 (no) MDR-reverseringsmidler
FR2687679B1 (fr) Oligothionucleotides.
FI921125A0 (fi) Ciclosporin.
DZ1920A1 (fr) Benzoxazolyl-et benzothiazolyloxazolidinones.
DK0682865T3 (da) Synergistiske blandinger med 1,2,4-triazoler
FI922003A0 (fi) Skakare/inkubator.
CH0673730H1 (fr) Fraiseuse.
FI960068A (fi) Paperinvalmistus
DE69403081T2 (de) Gleitlager